Now in its sixteenth year, the BIO CEO & Investor Conference is the largest independent investor
conference focused on leading publicly-traded biotech companies, with a special focus on select established
private companies. The meeting provides a neutral forum where institutional investors, industry analysts,
and senior biotechnology executives have the opportunity to shape the future investment landscape of the
Fenwick & West partner Effie Toshav will moderate a panel on February 11.
Let's Make a Deal - Strategic Licensing and M&A Trends
This panel will evaluate licensing and M&A trends of recent deals as the parties involved aim to get the biggest bang for their
buck. Why have these trends developed and what is in store for the future? What do company executives and investors think
about recent valuations, CVRs, and the timing of deals with respect to stage of development? Hear industry experts speak on
the differing licensing challenges and solutions facing both large and small companies.
Michael Diem, Global Vice President & Head of Corporate Strategy, AstraZeneca
David H. Donabedian, PhD, Vice President, Head of Venture Investments & Early Stage Collaborations, AbbVie